- Homology Medicines (NASDAQ:FIXX) initiated with Buy rating and $27 (32% upside) price target at BofAMerrill Lynch. Initiated with Outperform rating at Cowen and Company. Shares up 3% premarket.
- Knight Therapeutics (OTC:KHTRF) initiated with Outperform rating and C$9.50 (22% upside) price target at RBC.
- Unum Therapeutics (NASDAQ:UMRX) initiated with Overweight rating and $20 (67% upside) price target at Morgan Stanley (NYSE:MS). Initiated with Market Perform rating at Cowen. Shares up 3% premarket.
- Cerner (NASDAQ:CERN) upgraded to Buy at Citigroup (NYSE:C). Shares up 3% premarket.
- Insmed (NASDAQ:INSM) upgraded to Outperform at Credit Suisse (SIX:CSGN). Shares up 4% premarket.
- Merck (NYSE:MRK) upgraded to Buy with a $73 (24% upside) price target at Goldman Sachs (NYSE:GS) citing Keytruda upside (sales target doubled to $4B in 2025). Added to Conviction List. Shares up 2% premarket.
- Spark Therapeutics (NASDAQ:ONCE) downgraded to Neutral with an $85 (4% upside) price target at Chardan Capital Markets. Shares down 1% premarket.
- Now read: Cerner (CERN) Investor Presentation - Slideshow
Original article